EP1357914A2 - Verfahren zur behandlung von ppar vermittelten krankheiten - Google Patents

Verfahren zur behandlung von ppar vermittelten krankheiten

Info

Publication number
EP1357914A2
EP1357914A2 EP02709285A EP02709285A EP1357914A2 EP 1357914 A2 EP1357914 A2 EP 1357914A2 EP 02709285 A EP02709285 A EP 02709285A EP 02709285 A EP02709285 A EP 02709285A EP 1357914 A2 EP1357914 A2 EP 1357914A2
Authority
EP
European Patent Office
Prior art keywords
ppar
treatment
expression
abca1
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02709285A
Other languages
English (en)
French (fr)
Inventor
Timothy Mark Willson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1357914A2 publication Critical patent/EP1357914A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention is in the field of pharmacology and medicine. More particularly this invention relates to methods of identifying suitable treatment regimes for diseases or conditions mediated by Peroxisome Proliferator- Activated Receptors (PPARs), particularly those mediated by PPAR delta. In another aspect the invention provides a method of promoting reverse cholesterol transport in an individual.
  • PPARs Peroxisome Proliferator- Activated Receptors
  • lipid homestasis is a delicate balance between dietary intake, de novo synthesis and catabolism.
  • the increased incidence of cardiovascular disease in Westernized countries has been linked to dyslipidemias associated with changes in the fat content of the diet (1).
  • Obesity, insulin resistance and hypertension are comorbidities with these lipid disorders, which together are known as the metabolic syndrome X (2).
  • Individuals with this condition have raised serum triglycerides and abnormally low levels of high density lipoprotein cholesterol (HDLc) (2, 3).
  • HDLc high density lipoprotein cholesterol
  • HDL plays a protective role through the process of "reverse cholesterol transport" whereby cholesterol is removed from peripheral cells, including the macrophage-derived foam cells, and returned to the liver (5).
  • Agents that raise the levels of HDL by stimulating reverse cholesterol transport would provide a new therapeutic option for the prevention of atherosclerotic cardiovascular disease (6).
  • ABC1 ATP-binding cassette A1
  • Fibrates are a class of drugs that have been used for decades for their beneficial effects on serum lipids. Although fibrates are predominantly triglyceride-lowering drugs that only modestly raise HDLc (12, 13), clinical trials have shown that they lower the incidence of atherosclerosis and coronary artery disease in patients with normal levels of LDLc (12, 14). Most fibrate drugs are only weakly active on human PPAR and show low selectivity over human PPAR ⁇ and PPAR ⁇ (15).
  • PPAR ⁇ increases cholesterol efflux from cells through an increase in the expression of the ABCA1 cholesterol and phospholipid transporter.
  • ABCA1 cholesterol and phospholipid transporter These data and its broad tissue distribution suggest that PPAR ⁇ is an important regulator of reverse cholesterol transport in mammals, and thus has unique pharmacology that distinguishes it from the other PPAR subtypes.
  • PPAR ⁇ modulators may therefore provide a new approach to the treatment of cardiovascular disease by promoting reverse cholesterol transport, an effect not previously associated with PPAR delta. It would be desirable to test the effectiveness of drugs for PPAR delta mediated diseases or conditions. Measuring blood HDLc levels may indicate HDLc is increased but will not indicate the mechanism by which this occurs and thus whether the HDLc increase is clinically beneficial.
  • ABCA1 may be used as a surrogate marker for measuring activity of PPAR delta and therefore indicating the level of reverse cholesterol transport as well as increase in HDLc. This would provide a more objective standard and a test by which a drug could be tested for its effectiveness in individuals.
  • the present invention provides a method of increasing ABCA1 activity and/or expression and promoting reverse cholesterol transport in a subject, comprising administering to the subject a therapeutically effective amount of an modulator of PPAR delta.
  • the present invention provides the use of a PPAR delta modulator for the manufacture of a medicament for the purpose of increasing ABCA1 activity and/or expression and promoting reverse cholesterol transport in a subject.
  • This invention also provides a method for testing a compound or composition for the treatment of a PPAR mediated disease or condition.
  • the method comprises administering a PPAR delta modulator against one or more subjects and determining the level of ABCA1 expression and/or activity.
  • This method is also useful in determining the level of efficacy of a treatment with a PPAR delta modulator, depending upon the extent to which the treatment can cause ABCA1 expression and/or activity.
  • the present invention extends to the use of a compound or composition identified by this method in the manufacture of a medicament for the treatment of PPAR mediated diseases or conditions in a patient in need thereof and a method of treatment of PPAR mediated diseases or conditions which comprises the administration of a therapeutically effective amount of a compound identified by the above method to a patient in need thereof.
  • the invention also provides a method for identifying a suitable treatment regime for treating a PPAR mediated disease or condition in an individual. The method involves determining a regime for a compound or composition which increases ABCA1 expression and/or activity comprising administering a compound, measuring ABCA1 expression and/or activity whereby the determined regime provides an effective treatment.
  • Fig. 1 Regulation of ABCA1 expression and cholesterol efflux from THP1 macrophages. Compounds were used at the following concentrations: PPAR ⁇ (GW501516), 100 nM; PPAR ⁇ (GW7647), 100 nM; PPAR ⁇ (GW7845), 100 nM. Data are presented as the mean of assays performed in triplicate ⁇ S. D A. ABCA1 mRNA levels determined by RTQ-PCR. ⁇ . ApoA1 -specific cholesterol efflux.
  • hPPAR mediated diseases or conditions include dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia, syndrome X (as defined in this application this embraces metabolic syndrome), heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa.
  • Particular diseases include diabetes and cardiovascular diseases and conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidaemia
  • the methods of this invention employing ABCA1 as a surrogate marker can be used at any stage, including during clinical trial or after approval of a pharmaceutical product by the appropriate regulatory authority (e.g. the United States Food and Drug Administration).
  • the pharmaceutical product comprises a PPAR delta modulator that is not known for effectiveness in PPAR mediated diseases or that has not been approved for use in PPAR mediated diseases.
  • PPAR delta modulating compounds or compositions that already have been approved can be tested according to the invention also.
  • the treatment regime can include any factors relating to the treatment, including, without limitation, the identity of the drug or drugs administered, the amount administered, the timing of delivery, if the regime involves a combination of one or more drugs, the ratio of drugs in combination and their interaction, the route of delivery, and the pharmaceutical formulation employed.
  • the method can be performed on groups of individuals or on a single individual. Performing the method on a single individual, especially one who suffers from a PPAR mediated disease or condition, is useful in order to determine a customised treatment for protocol for the individual. Groups of individuals are useful in order to obtain data for statistical analysis in order to identify treatment protocols for a population in general.
  • the groups of individuals can be individuals who suffer from a PPAR mediated disease or condition or alternatively, because the methods use surrogate markers, the subjects can be persons who do not suffer from a PPAR mediated disease or condition.
  • the number of persons in a study is at the discretion of the researcher, who normally will use standard protocols for obtaining statistically significant results.
  • the protocol can be supplied as a label on a package containing the drug and the protocol can be administered to a patient.
  • composition refers to a composition of at least one drug to be tested. Accordingly, the composition can be a mixture of more than one drug provided in various ratios.
  • the composition generally will be administered in the form of a composition comprising at least two drugs in a particular ratio.
  • the invention involves testing different ratios of various drugs to identify ratios that cause an inhibition of a reflux inhibition of a surrogate market. Alternatively, drugs can be administered separately in different timing schedules.
  • the drugs tested generally will be PPAR delta modulators. Other agents, which may not themselves display efficacy but which potentiate the effacy of other agents may also be used.
  • the drugs are hPPAR ⁇ agonists.
  • agonist or “activating compound”, or “activator”, or the like, is meant those compounds which have a pKi of at least 6.0, preferably at least 7.0, to the relevant PPAR, for example hPPAR ⁇ in the binding assay described in WO01/00603, and which achieve at least 50% activation of the relevant PPAR relative to the appropriate indicated positive control in the transfection assay described at concentrations of 10 "5 M or less.
  • the agonist of this invention achieve 50% activation of human PPAR ⁇ in the transfection assay at concentrations of 10 "7 M or less, more preferably 10 "9 M or less.
  • the drugs are selective hPPAR ⁇ agonists.
  • a "selective hPPAR ⁇ agonist” is a hPPAR ⁇ agonist whose EC50 for PPAR ⁇ is at least 10 fold lower than its EC50 for PPAR ⁇ and PPAR ⁇ .
  • Such selective compounds may be referred to as "10-fold selective.”
  • EC50 is defined in the transfection assay described in WO01/00603 and is the concentration at which a compound achieves 50% of its maximum activity. Most pr -ferred compounds are greater than 100-fold selective hPPAR ⁇ agonists.
  • the therapeutic protocol is tested as a function of its ability to cause PPAR delta activation. Because there is no simple way to directly measure PPAR delta agonist activity, this invention relies on the use of ABCA1 as a surrogate marker.
  • a "surrogate marker" for activity of PPAR delta is a marker that indicates increased or decreased activity of PPAR delta.
  • ABCA1 activity is easy to measure, ABCA1 expression and/or activity is a preferred surrogate marker for this invention. This can be measured under many different conditions. These include, e.g., ABCAI mRNA levels in blood or tissues using Taq Man, Quantigene or Northern blot. ABCA1 protein levels could be measured by using a specific antibody and ELISA.
  • Effectiveness of the treatment generally will coincide with the time ABCA1 expression and/or activity occurs, indicating reverse cholesterol transport. Therefore, it is useful to test for activity over the course of minutes or hours after administration of the drug. However, detecting increased ABCA1 expression and/or activity at any time after administration of the drug is a positive indication of efficacy.
  • a certain amount of a drug usually is necessary to obtain any pharmacological effect. Overdoses of a drug can have harmful side effects. Similarly, because it effects bioavailability, among other things, routes of administration also effect efficacy. Thus, this invention contemplates determining the effect of dose or route of administration, alone or together, as part of determining a ABCA1 activity formulation and dosing regime.
  • the dose administered will be a dose within a range determined to be safe.
  • dosage amounts will be between about 0.02-5000mg per day.
  • composition can be formulated for administration in a variety of ways.
  • Typical routes of administration include both enteral and parenteral. These include, without limitation, subcutaneous, intramuscular, intravenous, intraperitoneal, intramedullary, intrapericardiac, intrabursal, oral, sublingual, ocular, nasal, topical, transdermal, transmucosal, or anal.
  • the mode of administration can be, eg. via swallowing, inhalation, injection or topical application to a surface (e.g., eyes, mucus membrane, skin).
  • the formulation can be in any of the usual forms, including aqueous solution, for enteral, parenteral or transmucosal administration, e.g., for intravenous administration, as liquid formulations and administration to mucus or other membranes as, for example, nose (nasal) or eye drops; solid and other non-aqueous compositions for enteral or transdermal delivery e.g., as pills, tablets, powders, ointments, suppositories or capsules; transdermal, transmucosal or rectal delivery systems for topical administration, and aerosols or mists for delivery by inhalation.
  • aqueous solution for enteral, parenteral or transmucosal administration, e.g., for intravenous administration, as liquid formulations and administration to mucus or other membranes as, for example, nose (nasal) or eye drops
  • solid and other non-aqueous compositions for enteral or transdermal delivery e.g., as pills, tablets,
  • Another parameter of the treatment regime can be timing of administration, e.g., time between doses, timed release of doses, etc.
  • Testing may indicate that treatment regime results in no change in the surrogate marker, an inhibition of the marker or a stimulation of the marker. Those that cause, increase in activity of the surrogate marker within a safe range indicate useful protocols for delivery of the drug for therapeutic treatment.
  • This invention allows one to determine level of efficacy of a treatment.
  • Compounds known to be effective in the treatment of PPAR mediated diseases can be tested to determine the level of ABCA1 activity and a standard set up relating amount of ABCA1 activity with amount of efficacy. Then, a ' composition can be tested in a treatment regime and the level of ABCA1 activity measured. This level is then compared with the standard curve to determine the expected level of efficacy.
  • THP1 human monocyte cells (ATCC TID-202), in 6-well plates at a density of 1 x 10 6 cells/well in RPMI 1640 medium containing 10% FBS, were differentiated into macrophages by treatment with PMA (100 ng/ml) for 5 days.
  • PMA 100 ng/ml
  • Total RNA was generated using the Qiagen RNeasy Mini Kit and DNase treated according to the manufacturer's protocol (Ambion).
  • ABCA1 expression was analysed using RTQ- PCR on an ABI PRISM 7700 sequence detection system (P. E. Applied Biosystems). Primer/probe sequences used were as follows: ABCA1 forward primer ⁇ '-TGTCCAGTCCAGTAATGGTTCTGTGT-S' , (Seq ID No:1 ) reverse primer 5'-GCGAGATATGGTCCGGATTG-3 ⁇ (Seq ID No:2) probe 5'FAM- ACACCTGGAGAGAAGCTTTCAACGAGACTAACC-TAMRA3'( Seq ID No:3) Expression data were normalised to 18S as described by the vendor.
  • THP1 cells were washed in serum-free medium and incubated in 5% FBS medium containing 1 ⁇ Ci/mL of [ 3 H]- cholesterol (New England Nuclear) and 0.2% fatty acid-free BSA (faf BSA) for a further 24 h.
  • the cells were washed in serum-free medium and then incubated for 24 h in serum-free medium supplemented with 1.5% faf BSA ⁇ test compound or vehicle (0.1 % DMSO). The equilibration medium was removed and the cells washed twice in serum-free medium.
  • Serum-free DMEM containing compound ⁇ purified human apolipoprotein (apo) Al (10 mg/ml, Athens Research & Technology) was added. The cells were maintained for 24 h before medium and cell extract samples were generated. Scintillation counting was performed to determine the percentage cellular cholesterol efflux ⁇ apoAI.
  • 1 BR3N human skin fibroblast cells were plated in 6-well plates at a density of 1 x 10? cells/well in DMEM medium containing 10% FBS and cultured for 24 h. Efflux studies were performed as in the THP1 macrophages except that the cells were maintained for 48 h before scintillation counting was performed.
  • THP1 macrophages were dosed with ligands selective for each of the three subtypes.
  • the PPAR ⁇ agonist GW501516 showed strong induction of ABCA1 mRNA expression (Fig. 1A).
  • the PPAR ⁇ agonist GW7845 also induced ABCA1 expression, while the PPAR ⁇ agonist GW7647 showed only a weak effect.
  • the PPAR ⁇ agonist GW501516 produced a 2-fold increase in cholesterol efflux to apoAI (Fig. 1B and Table 1).
  • PPAR ⁇ regulates cholesterol efflux from macrophages.
  • both the PPAR ⁇ and PPAR ⁇ agonists were ineffective, despite their ability to produce small increases in ABCA1 expression in these cells.
  • Percent increase was calculated from (GW-vehicle) ⁇ tehicle x 100. Data are presented as the mean of assays performed in triplicate ⁇ S. D. N. D., not determined.
  • PPAR ⁇ is expressed in many tissues that contribute to cholesterol flux (22).
  • GW501516 in human fibroblast and intestinal cell lines (Table 1).
  • 1BR3N human skin fibroblasts the selective PPAR ⁇ agonist produced a 3.4-fold increase in ABCA1 expression and a 2-fold increase in apoA1 -specific cholesterol efflux.
  • FHS74 human intestinal cells 23
  • the selective PPAR ⁇ agonist produced a 2.1 -fold increase in ABCA1 expression.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
EP02709285A 2001-02-02 2002-01-31 Verfahren zur behandlung von ppar vermittelten krankheiten Withdrawn EP1357914A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26639301P 2001-02-02 2001-02-02
US266393P 2001-02-02
PCT/US2002/003017 WO2002070011A2 (en) 2001-02-02 2002-01-31 Treatment of ppar mediated diseases

Publications (1)

Publication Number Publication Date
EP1357914A2 true EP1357914A2 (de) 2003-11-05

Family

ID=23014384

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02709285A Withdrawn EP1357914A2 (de) 2001-02-02 2002-01-31 Verfahren zur behandlung von ppar vermittelten krankheiten

Country Status (3)

Country Link
EP (1) EP1357914A2 (de)
AU (1) AU2002243778A1 (de)
WO (1) WO2002070011A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
EP1999098A2 (de) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Verbindungen, die die ppar-aktivität modulieren, ihre herstellung und ihre verwendung
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
AU1303301A (en) * 1999-11-10 2001-06-06 Takeda Chemical Industries Ltd. Body weight gain inhibitors
MXPA02007603A (es) * 2000-03-09 2003-02-24 Aventis Pharma Gmbh Usos terapeuticos de mediadores ppar.
JP2001354671A (ja) * 2000-04-14 2001-12-25 Nippon Chemiphar Co Ltd ペルオキシソーム増殖剤応答性受容体δの活性化剤
AU2001277926B2 (en) * 2000-07-20 2006-02-16 Bristol-Myers Squibb Company Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
JP4790969B2 (ja) * 2000-08-11 2011-10-12 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
JPWO2002046154A1 (ja) * 2000-12-05 2004-04-08 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体δの活性化剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02070011A2 *

Also Published As

Publication number Publication date
WO2002070011A3 (en) 2003-04-24
WO2002070011A2 (en) 2002-09-12
AU2002243778A1 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
CA2204616C (en) Ppar gamma antagonists for treating obesity
AU2003298926C1 (en) Fat regulation
JP5460600B2 (ja) 肥満症治療における肥満細胞安定化薬
WO1998005331A2 (en) Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US20080241869A1 (en) Compositions and methods for ameliorating hyperlipidemia
WO2003008967A1 (en) Method of selecting substance characterized by assaying ppard activating effect and drug
TW201033182A (en) Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
JP2019509278A (ja) Ｆｘｒアゴニストを使用するための方法
TW200803896A (en) Method of improvement of cognitive function
WO2002070011A2 (en) Treatment of ppar mediated diseases
WO2021197396A1 (zh) 氘代氧化苯砷化合物及其应用
US20090042835A1 (en) Compositions and methods for ameliorating hyperlipidemia
US20080279843A1 (en) Method For Improving Insulin Sensitivity By Administering an Inhibitor of Antitrypsin
US20020165119A1 (en) Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
AU2001277926B2 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
US20040138094A1 (en) Treatment regimes
JP2008528694A (ja) 糖尿病の治療または予防において使用するためのニトロキシド類
AU2001277926A1 (en) Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
JP7577191B2 (ja) フェニルアルキルカルバマート化合物を含むｋｃａ３．１チャネル介在性疾患治療用組成物
WO2018015862A1 (en) 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
KR100944397B1 (ko) 데커시놀을 유효 성분으로 포함하는 비만 예방 및 치료용조성물
WO2021053618A1 (en) Treatment comprising fxr agonists
JP7048863B2 (ja) 非アルコール性脂肪肝疾患の治療法
TWI862935B (zh) 羅索沙星在治療和/或預防慢性肝臟疾病上的用途
Ding et al. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Q9 Cilofexor/Firsocostat Q1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FOX, JENNIFER L.GLAXOSMITHKLINE

Inventor name: WILLSON, TIMOTHY MARK

17Q First examination report despatched

Effective date: 20040216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080801